(Q40780267)

23 September 2017

title

Bortezomib Inhibits Osteoclastogenesis and Porphyromonas gingivalis Lipopolysaccharide-induced Alveolar Bone Resorption (English)

1 reference

23 September 2017

main subject

Porphyromonas gingivalis

0 references

lipopolysaccharide

0 references

author name string

Y-G Kim

1

1 reference

23 September 2017

J H Kang

2

1 reference

23 September 2017

H J Kim

3

1 reference

23 September 2017

H J Kim

4

1 reference

23 September 2017

H-H Kim

5

1 reference

23 September 2017

J-Y Kim

6

1 reference

23 September 2017

Y Lee

7

1 reference

23 September 2017

language of work or name

English

0 references

publication date

30 June 2015

1 reference

Journal of Dental Research

23 September 2017

published in

1 reference

23 September 2017

volume

94

1 reference

23 September 2017

issue

9

1 reference

23 September 2017

page(s)

1243-1250

1 reference

Autoamplification of NFATc1 expression determines its essential role in bone homeostasis

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

The molecular understanding of osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

The effects of bortezomib on bone disease in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Genetic regulation of osteoclast development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Bortezomib inhibits human osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Impact of bortezomib on bone health in myeloma: a review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0022034515592592

21 January 2018

Identifiers

DOI

10.1177/0022034515592592

1 reference

23 September 2017

1 reference